Atriva Therapeutics announces first closing of series A financing round Funds to advance antiviral lead product ATR-002 into clinical trials Tübingen (Germany), January 3, 2019 – Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech…